Erik brings over 20 years of finance and biotech operating experience, including a focus on rare diseases and cell-based therapies. He was previously CFO at Summit Therapeutics, where he led the finance and investor relations functions and played a key role in multiple strategic transactions to build out the company’s U.S. and global operations.

Prior to joining Summit, Erik was vice president of finance at Organogenesis Inc. He previously worked in investment banking, including as a director of healthcare investment banking with Leerink Partners. Erik began his career as an accountant with PricewaterhouseCoopers and received a BS in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.